Augmentation of Antipsychotic Medications with Low-Dose Clozapine in Treatment-Resistant Schizophrenia—Case Reports and Discussion
Author(s) -
Zoe Harrison,
Owen Haeney,
William Brereton
Publication year - 2021
Publication title -
case reports in psychiatry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.17
H-Index - 4
eISSN - 2090-682X
pISSN - 2090-6838
DOI - 10.1155/2021/5525398
Subject(s) - clozapine , tolerability , schizophrenia (object oriented programming) , antipsychotic , medicine , psychiatry , clinical practice , antipsychotic drug , rehabilitation , intensive care medicine , adverse effect , physical therapy
Treatment resistance in schizophrenia is often encountered in clinical practice, with clozapine usually recommended as the appropriate therapy. However, where clozapine proves ineffective or cannot be tolerated due to side effects, treatment options are limited. In patients within forensic mental health services, residual symptomatology often presents a barrier to discharge and can have lasting effects on prospects for rehabilitation as well as risk to self and others. This paper presents a review of the relevant literature and three cases of a novel approach, utilising clozapine in doses usually considered subtherapeutic, in combination with the primary antipsychotic treatment. In all three patients, it improved clinical efficacy as well as tolerability, resulting in improvement that allowed discharge from the forensic hospital.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom